Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Artiva Biotherapeutics, Inc. (ARTV)
Company Research
Source: Yahoo! Finance
Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indications Treated first patient in Artiva sponsored Phase 1/1b trial in patients with class III or IV lupus nephritis (LN) and expanded trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent progress. “Artiva is at an inflection point as we advance AlloNK® in clinical development across multiple autoimmune indications and transition to a publicly traded company,” said Fred Aslan, M.D., Artiva's Chief Executive Officer. “With two trials in autoimmunity unde
Show less
Read more
Impact Snapshot
Event Time:
ARTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTV alerts
High impacting Artiva Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ARTV
News
- Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.MarketBeat
- Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire
- Artiva Biotherapeutics to Participate in the Jefferies London Healthcare ConferenceGlobeNewswire
- Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of DirectorsGlobeNewswire
- Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity [Yahoo! Finance]Yahoo! Finance
ARTV
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- ARTV's page on the SEC website